Viam, the engineering platform for data, AI and automation, today announced a partnership with Viking Yachts, a global leader in sportfishing and cruising yachts with 1 million square feet of ...

Viking's VK2735 GLP-1/GIP dual-agonist delivered a 15% weight loss in just 13 weeks during its Phase 2 VENTURE trial, demonstrating rapid efficacy that far outpaces the baseline trajectories of ...

Viking Holdings (NYSE:VIK) recently completed a significant Follow-on Equity Offering, raising $1.35 billion by issuing over 30 million shares at $44.20 each. This capital-raising effort may have ...

In order to reconstruct their seafaring itineraries, Lund University archaeologist Greer Jarrett sailed functional Viking-like boats along the Norwegian coast in a series of experimental voyages.

Viking (VIK) Q1 2025 Earnings Call Transcript May 20, 2025 — 04:08 pm EDT. Written by Motley Fool Transcribing for The Motley Fool- ...

Viking slashed its loss by 79% year-over-year to $105.5 million, and its loss per share of $0.24 was $0.03 better than forecasts. Revenue rose 25% to $897.1 million, also more than expected.

Viking Sky Disaster - 1,000 Trapped as Ship Fails in a Deadly Storm. Posted: May 20, 2025 | Last updated: May 20, 2025. Waves smashed windows, water flooded in, and over 1,000 passengers waited as ...

Archaeologists in Sweden found an exceptional Viking coffin with weapons. The rare discovery near Linköping offers valuable insights into Viking funeral customs and social hierarchy.

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

The Waterford Viking Marathon returns this June for its 13th year, and it's quickly becoming one of Ireland's most loved running events. Last summer, the streets were buzzing.

Viking says it can also up its orders from CordenPharma in the future, if it so chooses. The biotech will dish out the $150 million for the deal in the form of prepayments to CordenPharma from ...

Viking Therapeutics (VKTX-9.04%) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss.